Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

Lai-Ping Zhong¹, Dong-Wang Zhu¹, William N. William Jr³, Ying Liu¹, Jie Ma¹, Cheng-Zhe Yang¹, Xiao Yang¹, Li-Zhen Wang², Jiang Li², Jeffrey N. Myers⁴, J. Jack Lee⁵, Chen-Ping Zhang¹, and Zhi-Yuan Zhang¹

Abstract

Induction chemotherapy is likely to be effective for biologically distinct subgroups of patients with cancer with biomarker detection. To investigate the prognostic and predictive values of cyclin D1 expression in patients with oral squamous cell carcinoma (OSCC) who were treated in a prospective, randomized, phase III trial evaluating standard treatment with surgery and postoperative radiotherapy preceded or not by induction docetaxel, cisplatin, and 5-fluorouracil (TPF), immunohistochemical staining for cyclin D1 was conducted in pretreatment biopsy specimens of 232 out of 256 clinical stage III/IVA OSCC patients randomized to the clinical trial. Cyclin D1 index was estimated as the proportion of tumor cells with cyclin D1 nuclear staining. A low cyclin D1 expression predicted significantly better overall survival (OS; \( P = 0.001 \)), disease-free survival (DFS; \( P = 0.005 \)), locoregional recurrence-free survival (\( P = 0.003 \)), and distant metastasis-free survival (DMFS; \( P = 0.002 \)) compared with high cyclin D1 expression. Cyclin D1 expression levels were not predictive of benefit from induction TPF in the population overall. However, patients with nodal stage cN2 whose tumors had high cyclin D1 expression treated with TPF had significantly greater OS (\( P = 0.025 \)) and DMFS (\( P = 0.025 \)) when compared with high cyclin D1 cN2 patients treated with surgery upfront. Patients with low cyclin D1 level or patients with cN0 or cN1 disease did not benefit from induction chemotherapy. This study indicates that cN2 OSCC patients with high cyclin D1 expression can benefit from the addition of TPF induction chemotherapy to standard treatment. Cyclin D1 expression could be used as a biomarker in further validation studies to select cN2 patients that could benefit from induction therapy.

Introduction

Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the oral and maxillofacial region, with about 300,000 new cases worldwide each year (1, 2). Many efforts have been made to improve the diagnosis and treatment of patients with OSCC; however, the prognosis is still poor with a 5-year survival rate of approximately 50% to 60% (3, 4), with even poorer outcomes noted in those patients with local-regionally advanced disease. For patients with resectable locally advanced OSCC, the most commonly recommended treatment is radical surgery followed by postoperative radiotherapy or chemoradiotherapy depending on the presence of high-risk features in the surgical specimen.

Induction chemotherapy has been investigated as a possible strategy to shrink or downstage locally advanced head and neck cancers, increase organ preservation rates, and/or reduce the risk of locoregional and/or distant recurrence, ultimately improving treatment outcomes. Induction chemotherapy with a combination of docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiotherapy or chemoradiotherapy has been shown to improve overall survival (OS) compared with induction chemotherapy with cisplatin and 5-fluorouracil (PF) in 2 randomized phase III trials (TAX323 and TAX324; refs. 5–7). As a result, TPF is suggested as the preferred combination chemotherapy regimen when induction treatment is used for nonsurgical management of patients with squamous cell carcinoma of the head and neck (HNSCC). Despite the potential benefits seen in these initial studies, the role of TPF induction
chemotherapy for nonsurgical management of HNSCCs has been questioned especially after presentation of the results of the recently completed DeCIDE and PARADIGM trials. These studies compared chemoradiotherapy upfront versus induction TPF followed by chemoradiotherapy, and failed to show a significant improvement in OS or disease-free survival (DFS) for patients receiving TPF (8, 9).

To address the role of induction TPF in HNSCC treated with surgery (as opposed to the nonsurgical approach used in the aforementioned studies), we recently conducted and presented the results of a randomized, phase III trial of induction TPF followed by surgical resection versus surgical resection upfront in patients with locally advanced OSCC (10). In concert with DeCIDE and PARADIGM, we were also unable to show a survival advantage for induction chemotherapy in the overall study population. Taken together, these data show that induction chemotherapy should not be universally integrated into nonsurgical or surgical management of patients with OSCC. It is possible, however, that induction chemotherapy with TPF might improve outcomes in molecularly defined subgroups of patients, and correlative studies from the aforementioned randomized trials could assist in identifying candidate biomarkers predictive of benefit from induction treatment.

The cyclin D1 gene is a proto-oncogene located on chromosome 11q13, which encodes the cyclin D1 nuclear protein, a positive cell-cycle regulator. Cyclin D1 binds and activates CDK4 and CDK6, forming a complex that catalyzes retinoblastoma (Rb) protein phosphorylation resulting in the release of transcriptional regulators E2F from Rb. This promotes cell-cycle progression from G1 to S-phase (11). Although increased expression of cyclin D1 in OSCC has been reported, there are controversial data on the prognostic value of cyclin D1 overexpression in OSCC. Some studies suggest that increased expression of cyclin D1 is associated with poor survival (12–16), whereas other studies show that cyclin D1 overexpression provides little prognostic information for patients with OSCC (17, 18).

The aim of this study is to evaluate cyclin D1 expression in the pretreatment biopsy samples from patients who had local-regionally advanced, resectable OSCC and had been enrolled in a randomized phase III trial of TPF induction chemotherapy followed by surgery and postoperative radiotherapy compared with upfront surgery and postoperative radiotherapy, and to examine its possible prognostic and predictive role in this patient population. We hypothesize that high levels of expression of cyclin D1 will be associated with shortened OS in patients treated with surgery upfront, but will be predictive of OS benefit from TPF induction chemotherapy.

Materials and Methods

Study population

This study was based on patients who were enrolled in a prospective, open label, randomized, phase III trial at the Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine (Shanghai, China), which aimed to test the hypothesis that TPF induction chemotherapy administered before surgery and postoperative radiotherapy would improve survival over surgery upfront in patients with resectable locally advanced OSCC (trial registration ID: NCT01542931). Details of the clinical trial have been previously described (10). Briefly, main eligibility criteria included resectable squamous cell carcinoma of the oral cavity, clinical stage III or IVA (T1-2N1-2M0 or T3-4N0-2M0, UICC 2002), Karnofsky performance status >60%, and adequate hematologic, hepatic, and renal function. Eligible patients were randomly allocated to the control arm (surgery followed by postoperative radiotherapy) or experimental arm (TPF induction chemotherapy followed by surgery and postoperative radiotherapy). TPF induction chemotherapy consisted of docetaxel 75mg/m² intravenously on day 1, followed by cisplatin 75mg/m² intravenously on day 1, followed by 5-fluorouracil 750mg/m²/day as a 120-hour continuous intravenous infusion on days 1 through 5, every 3 weeks for 2 cycles. Surgery was carried out at least 2 weeks after completion of induction chemotherapy and consisted of radical resection of the primary lesion and full neck dissection (functional or radical) with appropriate reconstruction (pedicle or free flap). Postoperative radiotherapy was initiated 4 to 6 weeks after surgery, at a dose of 1.8–2Gy/day, 5 days/week for 6 weeks, totally 54–60Gy; in patients with high-risk features, such as positive surgical margins, extracapsular nodal spread, or vascular embolism, a total radiation dose of 66Gy was recommended.

The clinical tumor response was determined by clinical evaluation and imaging studies (conducted at baseline and 2 weeks after cycle 2 of induction chemotherapy). Responses were characterized according to the RECIST version1.0 (19). The pathologic response to TPF induction chemotherapy was assessed by examination of at least 20 slides of the resected specimen. A favorable response was defined as absence of any tumor cells (pathologic complete response) or presence of scattered foci of a few tumor cells (minimal residual disease with <10% viable tumor cells), as previously described by Licitira and colleagues (20).

After treatment, patients were monitored every 3 months in the first 2 years, every 6 months in the subsequent 3 to 5 years, and once a year thereafter until death or data censoring.

Detection of cyclin D1 expression using immunohistochemistry

Pretreatment formalin-fixed and paraffin-embedded biopsy samples were collected for detection of cyclin D1 expression; however, in the control arm, if pretreatment biopsy was unavailable, a portion of the surgical resection specimen was collected for biomarker evaluation. Sections 4 μm thick were studied using both hematoxylin and eosin staining (for diagnostic confirmation according to the World Health Organization histologic criteria (21) and immunohistochemical staining for cyclin...
D1. Immunohistochemical staining was conducted as previously described (22, 23). In brief, after deparaffinization, endogenous peroxidase was blocked, and the sections were heated by water bath at 98°C with 0.01 mol/L citrate buffer solution (pH 6.0) for 20 minutes to retrieve antigen, and cooled at room temperature, then washed with PBS 3 times for 5 minutes each, then incubated with the rabbit monoclonal antibody to cyclin D1 (clone-EPR2241, Epitomics, Inc.) at 1:150 dilution overnight at 4°C. After recovering to room temperature for 1 hour, the sections were washed with PBS 3 times for 5 minutes each. Staining was then visualized using 3,3′-diaminobenzidine (DAB) detection kit of Dako Real EnVision Detection System, Peroxidase/DAB+, Rabbit/Mouse (Dako Cytomation). The 1:150 dilution was the most optimal when compared with 1:50, 1:100, and 1:200. A negative control was prepared using PBS instead of cyclin D1 antibody. Two pathologists blinded to the treatment groups scored the slides. Staining for cyclin D1 expression was observed in the cellular nucleus. The cyclin D1 expression index was determined on the basis of the proportion of stained cells using a semiquantitative scale: negative, ≤ 10% of stained cells; weak positive, <50% of stained cells; and strong positive, ≥ 50% of stained cells (Supplementary Fig. S1). Low cyclin D1 expression was defined as negative and weak positive cyclin D1 expression, whereas high cyclin D1 expression was defined as strong positive cyclin D1 expression. This was based on previous studies showing that the chosen cutoff of 50% was reasonable for prognostic analysis in OSCC (12, 24).

Statistical analysis
OS was calculated from the date of randomization to the date of death; DFS/locoregional recurrence-free survival (LRFS)/distant metastasis-free survival (DMFS) were calculated, respectively, from the date of randomization to recurrence/locoregional recurrence/distant metastasis or death from any cause.

For descriptive analysis, categorical data were expressed as number and percentage. The χ² test was applied to compare the difference between the baseline factors and cyclin D1 expression. The survival analysis was conducted using the Kaplan–Meier method and log-rank test. HR were calculated using the Cox proportional hazards model. The intention-to-treat principle was applied for efficacy analysis. All hypothesis-generating tests were 2-sided at a significance level of 0.05. Data were analyzed with the statistical software SPSS13.0 for Windows (SPSS Inc.)

Results
Patient characteristics and treatment outcomes
From March 2008 to December 2010, 256 eligible patients were enrolled in this study (128 patients in each arm), and 232 (91%, 127 patients in the control arm, 105 patients in the experimental arm) patients were assessed for pretreatment cyclin D1 expression levels in the tumor. The distribution of baseline characteristics in the subset of patients that had biomarker evaluation was similar to the distribution in the entire trial population (Table 1). No patients were lost to follow-up. The median follow-up time was 30 months among the censored patients.

As previously described, no significant differences in OS, DFS, LRFS, or DMFS could be identified between the experimental and control arms in the entire patient population (10). On exploratory analysis, cN2 patients benefited from TPF induction chemotherapy as regards to OS and DMFS (10). The same analysis was conducted in the 232 patients who had baseline cyclin D1 levels evaluated (Supplementary Fig. S2). In this subset, OS at 2 years for the control and experimental arms was 68.8% and 72.6%, respectively (P = 0.472). Disease-free survival at 2 years was 64.5% and 66.0%, respectively (P = 0.592). The locoregional recurrence rate and distant metastasis rate in the control arm were 30.5% and 8.7%, respectively; in the experimental arm, the locoregional recurrence rate and distant metastasis rate were 31.3% and 5.5%, respectively. As observed for the entire trial population, cN2 patients benefited from TPF induction chemotherapy as regards to OS and DMFS (Supplementary Table S1).

Cyclin D1 expression and baseline characteristics
Figure 1 shows the relative frequency distribution of cyclin D1 expression index in this study. A total of 155 samples (84 in the control arm and 71 in the experimental arm) were found to have low cyclin D1 expression, including 37 negative (19 in the control arm and 18 in the experimental arm) and 118 weak positive (65 in the control arm and 53 in the experimental arm). There were 77 samples (43 in the control arm and 34 in the experimental arm) with high cyclin D1 expression. The distribution pattern of cyclin D1 expression was balanced between the 2 arms (χ² test = 0.215, P = 0.898). There were no significant differences in cyclin D1 expression according to gender, age, primary tumor site, stage, grade, tobacco, or alcohol use (Table 1).

Cyclin D1 expression and patients’ outcomes
In the control arm, a low cyclin D1 expression predicted better outcomes with regard to OS, DFS, LRFS, and DMFS (Fig. 2). OS at 2 years was 76.3% and 53.7% in patients with low and high cyclin D1 expression, respectively (HR = 0.453; 95% CI 0.245–0.838; P = 0.012). DFS at 2 years was 68.7% and 56.5% in patients with low and high cyclin D1 expression, respectively (HR = 0.571; 95% CI 0.321–1.006; P = 0.053). The locoregional recurrence rate was 25.2% and 40.3% in the patients with low and high cyclin D1 expression, respectively; the distant metastasis rate was 5.2% and 9.1% in the patients with low and high cyclin D1 expression, respectively. The same association between high cyclin D1 expression levels and poor treatment outcomes (including OS, DFS, LRFS, and DMFS) were observed in patients treated with induction TPF (Fig. 3), and in patients when putting the 2 arms together (Supplementary Fig. S3). Exploratory subgroup analysis was conducted on the cyclin D1 expression according...
Female patients with low cyclin D1 expression had better outcomes, similar results were seen in elderly patients, patients with tongue cancer, patients with large tumor size, patients at clinical stage III, patients with moderately/poor differentiation grade, nonsmokers, and nondrinkers.

Univariate Cox model was used to analyze the impact of baseline characteristics and cyclin D1 expression on the time-to-event endpoints in the control and experimental arms, separately. Cyclin D1 expression (low vs. high), lymph node status (cN0-1 vs. cN2), and clinical stage (stage III vs. stage IVA) were identified as risk factors for OS, DFS, LRFS, and DMFS in the control arm.

Table 1. Baseline characteristics and cyclin D1 expression

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total patients N = 256</th>
<th>Cyclin D1 expression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low N = 155</td>
<td>High N = 77</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>179 (69.9)</td>
<td>103 (66.5)</td>
</tr>
<tr>
<td>Female</td>
<td>77 (30.1)</td>
<td>52 (33.5)</td>
</tr>
<tr>
<td>Age (y)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>168 (65.6)</td>
<td>105 (67.7)</td>
</tr>
<tr>
<td>≥60</td>
<td>88 (34.4)</td>
<td>50 (32.3)</td>
</tr>
<tr>
<td>Site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tongue</td>
<td>113 (44.1)</td>
<td>62 (40.0)</td>
</tr>
<tr>
<td>Buccal</td>
<td>45 (17.6)</td>
<td>31 (20.0)</td>
</tr>
<tr>
<td>Gingiva</td>
<td>40 (15.6)</td>
<td>28 (18.1)</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>30 (11.7)</td>
<td>18 (11.6)</td>
</tr>
<tr>
<td>Palate</td>
<td>18 (7.0)</td>
<td>10 (6.5)</td>
</tr>
<tr>
<td>Retromolar trigone</td>
<td>10 (3.9)</td>
<td>4 (2.6)</td>
</tr>
<tr>
<td>Clinical T descriptor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1/T2</td>
<td>66 (25.8)</td>
<td>42 (27.1)</td>
</tr>
<tr>
<td>T3/T4</td>
<td>190 (74.2)</td>
<td>113 (72.9)</td>
</tr>
<tr>
<td>Clinical N descriptor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>110 (43.0)</td>
<td>65 (41.9)</td>
</tr>
<tr>
<td>N1</td>
<td>94 (36.7)</td>
<td>59 (38.1)</td>
</tr>
<tr>
<td>N2</td>
<td>52 (20.3)</td>
<td>31 (20.0)</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>177 (69.1)</td>
<td>109 (70.3)</td>
</tr>
<tr>
<td>IVA</td>
<td>79 (30.9)</td>
<td>46 (29.7)</td>
</tr>
<tr>
<td>Pathologic differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>80 (31.2)</td>
<td>49 (31.6)</td>
</tr>
<tr>
<td>Moderately</td>
<td>165 (64.5)</td>
<td>98 (63.2)</td>
</tr>
<tr>
<td>Poorly</td>
<td>11 (4.3)</td>
<td>8 (5.2)</td>
</tr>
<tr>
<td>Smoking statusb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current/former</td>
<td>126 (49.2)</td>
<td>69 (44.5)</td>
</tr>
<tr>
<td>Never</td>
<td>130 (50.8)</td>
<td>68 (45.5)</td>
</tr>
<tr>
<td>Alcohol usec</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>98 (40.6)</td>
<td>54 (34.8)</td>
</tr>
<tr>
<td>Negative</td>
<td>158 (59.4)</td>
<td>101 (65.2)</td>
</tr>
</tbody>
</table>

*P value from the χ² test was reported to compare the difference between low and high cyclin D1 expression based on the different baseline factors.

bFormer/current smokers defined as at least one pack-year history of smoking.

cPositive alcohol use was defined as current alcohol use of more than one drink per day for 1 year (12 ounces of beer with 5% alcohol or 5 ounces of wine with 12%–15% alcohol or one ounce of liquor with 45%–60% alcohol). All other patients were classified as negative alcohol use.
arm; cyclin D1 expression (low vs. high) and clinical stage (stage III vs. stage IVA) were identified as risk factors for prognosis in the experimental arm (Supplementary Table S2). A multivariate Cox model analysis was conducted including cyclin D1 expression and lymph node status (clinical stage was not included because of the overlap between lymph node status and clinical stage) in the control arm, cyclin D1 expression, and clinical stage in the experimental arm. Cyclin D1 expression was found to be an independent risk factor for prognosis (Supplementary Table S3). Taken together, these data show that high level of expression of cyclin D1 is a poor prognostic biomarker in patients with OSCC.

**Cyclin D1 expression and response to induction chemotherapy**

In the experimental arm, the responses by RECIST in 105 patients with assessment of cyclin D1 that initiated induction chemotherapy were 78.1% clinical response (4 patients with complete response and 78 patients with partial response) and 18.1% clinical nonresponse (18 patients with stable disease and 1 patient with disease progression) and 4 patients were unevaluable for response. Favorable and unfavorable pathologic responses were observed in 26.7% (27/101) and 73.3% (74/101) of patients, respectively. Pathologic response could not be evaluated in 4 patients. Cyclin D1 expression did not correlate with clinical response to TPF induction chemotherapy ($\chi^2$ test = 2.297, $P = 0.130$), or pathologic response to induction chemotherapy ($\chi^2$ test = 0.763, $P = 0.382$; Supplementary Table S4).

**Cyclin D1 expression, treatment, and survival outcomes**

To assess whether cyclin D1 expression could serve as a predictive biomarker of benefit from induction chemotherapy, we analyzed the interaction between the biomarker, treatment, and survival outcomes. There were no significant differences in outcome between the experimental and control arms in patients with low cyclin D1 expression or in patients with high cyclin D1 expression (Table 2).

As previously described, both high cyclin D1 expression and cN2 were found to be associated with a higher risk for distant metastasis and reduced OS. We also showed that TPF improves OS and DMFS in the cN2 subgroup. To assess whether cyclin D1 expression could serve as a predictive biomarker of benefit from TPF in a subset of patients at high risk for distant metastases and death, we conducted an exploratory analysis of the interaction between cyclin D1, cN2, and survival outcomes. cN2 patients with high cyclin D1 expression benefited from TPF induction chemotherapy with respect to OS (HR = 5.888; 95% CI 1.097–31.613; $P = 0.025$) and DMFS (HR = 5.888; 95% CI 1.097–31.613; $P = 0.025$), whereas the cN2 patients with low cyclin D1 expression did not benefit from TPF induction chemotherapy (Fig. 4, Supplementary Table S5). In contrast, the cN0 and cN1 patients, with either low or high cyclin D1 expression, did not benefit from TPF induction chemotherapy with regard to OS, DFS, LRFS, and DMFS (Supplementary Table S5). There was no clear benefit from induction chemotherapy in any other subgroups (data not shown). Taken together, these exploratory analyses suggest that high expression level of cyclin D1 could serve as a predictive biomarker of benefit from induction chemotherapy in patients with OSCC with cN2 disease.

**Discussion**

In this study, we found that lower cyclin D1 expression in the pretreatment biopsy samples was a favorable prognostic biomarker, as it was associated with better OS, DFS, LRFS, and DMFS in patients with resectable locally advanced OSCC treated in a prospective, randomized, phase III trial. Cyclin D1 expression was not a predictive biomarker of benefit from induction TPF in the population overall. However, on exploratory analysis, patients with cN2 nodal staging and high cyclin D1 expression benefited from TPF induction chemotherapy in terms of OS and DMFS; whereas cN2 patients with low cyclin D1 expression did not derive benefit from induction treatment.

Cyclin D1 plays an important role in cell-cycle regulation. It forms a complex with and functions as a regulatory subunit of CDK4/CDK6, whose activity is required for cell-cycle G1→S transition through phosphorylation of the Rb protein (11). Therefore, cyclin D1 overexpression promotes cell growth as well as tumorigenesis. In OSCC, both cyclin D1 overexpression and
cyclin D1 gene amplification have been reported to correlate with adverse patients’ outcomes. Nimeus and colleagues and Miyamoto and colleagues have reported that the cyclin D1 gene amplification could be a more reliable biomarker of poor clinical outcomes than cyclin D1 overexpression (25, 26); however, data from Kami-nagakura and colleagues suggest that cyclin D1 gene amplification may not be useful for predicting the patients’ outcomes (15). Potential explanations for this observation include the fact that cyclin D1 protein expression can be upregulated by mechanisms other than gene amplification, such as increased transcription and impaired protein degradation (27–29). In addition, cyclin D1 protein levels can be increased by a posttranscriptional mechanism of Ras-dependent or Stat3-dependent induction (30, 31). As such, we opted to evaluate cyclin D1 protein expression as a potential prognostic and predictive biomarker in this study. To our knowledge, this is the first time that cyclin D1 is assessed in a cohort of patients prospectively followed within the context of a randomized induction chemotherapy trial.

We found that lower or absent cyclin D1 expression is independently associated with better outcome in univariate and multivariate analyses, findings that are in accordance with results from previous retrospective studies (12–16). Patients with low cyclin D1 expression also had a relatively lower tumor locoregional recurrence rate and distant metastasis rate after treatment compared with the patients with high cyclin D1 expression.

Cyclin D1 was found to have limited utility as a predictive biomarker of clinical or pathologic response to TPF.
Table 2. Survival comparison between the patients treated with and without TPF induction chemotherapy according to cyclin D1 expression

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>HR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with low cyclin D1 expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OS</td>
<td>0.857 (0.442–1.663)</td>
<td>0.649</td>
</tr>
<tr>
<td>DFS</td>
<td>0.797 (0.445–1.427)</td>
<td>0.445</td>
</tr>
<tr>
<td>LRFS</td>
<td>0.863 (0.477–1.559)</td>
<td>0.625</td>
</tr>
<tr>
<td>DMFS</td>
<td>0.736 (0.386–1.403)</td>
<td>0.351</td>
</tr>
<tr>
<td>Patients with high cyclin D1 expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OS</td>
<td>0.798 (0.403–1.681)</td>
<td>0.517</td>
</tr>
<tr>
<td>DFS</td>
<td>1.046 (0.551–1.984)</td>
<td>0.891</td>
</tr>
<tr>
<td>LRFS</td>
<td>1.046 (0.551–1.984)</td>
<td>0.891</td>
</tr>
<tr>
<td>DMFS</td>
<td>0.829 (0.418–1.641)</td>
<td>0.590</td>
</tr>
</tbody>
</table>

Figure 3. In the experimental arm, OS (A), DFS (B), LRFS (C), and DMFS (D) in patients with OSCC with low and high cyclin D1 expression.
induction chemotherapy when we looked at the entire cohort of patients that received neoadjuvant treatment. However, an exploratory subgroup analysis showed that cN2 patients with high cyclin D1 expression had higher DMFS when treated with TPF, which translated to an improvement in OS. Although this requires further validation in other datasets, one could envision a personalized treatment scenario in which patients with OSCC with cN2 disease with high cyclin D1 expression receive TPF induction chemotherapy before surgery, whereas those patients with low cyclin D1 expression are treated with surgery upfront, to avoid the toxicity from chemotherapeutic agents and the delay of definitive treatment.

Meta-analyses on induction chemotherapy in patients with HNSCC have reported that induction chemotherapy followed by locoregional treatment can significantly decrease 5-year distant metastasis rate (32, 33). The DeCIDE trial (8) and the study by Licitra and colleagues (20) also showed that induction chemotherapy reduces the risk of distant failure in this setting. In our prospective clinical trial, induction TPF also reduced the risk of distant failure rate from 8.7% to 5.5%, although the difference was not statistically significant. As shown by the correlative studies presented herein, integration of evaluation of biomarkers such as cyclin D1 into the overall work-up and treatment strategy of locally advanced patients with HNSCC may allow for a more accurate identification of individuals that are at highest risk of distant recurrence and that may potentially benefit from addition of systemic therapy before definitive treatment.

A limitation of our study, however, includes the fact that only 47 cN2 patients were assessed for cyclin D1 expression.

Figure 4. OS (A and B) and DMFS (C and D) in cN2 OSCC patients in the experimental and control arms according to the low cyclin D1 expression (A and C) and high cyclin D1 expression (B and D).
expression in the pretreatment biopsy samples. As such, these results need to be considered exploratory and hypothesis generating, and clearly need to be confirmed in further clinical trials with larger sample sizes.

In addition to our findings related to cyclin D1 expression, other biomarkers have been evaluated as potential predictors of benefit from induction treatment by other groups: p53 gene mutations have been found to be strongly associated with lower response rates to PF induction chemotherapy (34, 35); β-tubulin and Bcl-xl (36–38) have also been found to be prognostic and predictive biomarkers in patients with HNSCC receiving induction TPF or PF. However, before being widely embraced, further clinical trials using cyclin D1 and other prognostic and/or predictive biomarkers are needed to validate their clinical utility and to realize the goal of personalized treatment of patients with HNSCC based on their biomarker blueprint.

In conclusion, our study suggests that cyclin D1 high expression level should be considered a prognostic biomarker of poor outcomes in patients with resectable locally advanced OSCC, and as a possible predictive biomarker of benefit from TPF induction chemotherapy in patients with cN2 disease. On the basis of these findings, we plan to launch a randomized study of induction TPF in patients with cN2 OSCC, prospectively embedding cyclin D1 expression as a predictive biomarker in the clinical trial design. This will hopefully contribute to the development of a personalized induction treatment strategy for HNSCC.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: L.-P. Zhong, W.N. William Jr, Z.-Y. Zhang
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L.-P. Zhong, D.-W. Zhu, Y. Liu, J. Ma, C.-Z. Yang, X. Yang, L.-Z. Wang, J. Li, C.-P. Zhang, Z.-Y. Zhang
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L.-P. Zhong, C.-P. Zhang, Z.-Y. Zhang
Study supervision: Z.-Y. Zhang

Acknowledgments
The authors thank Drs. Han-bing Fu and Ting Gu for providing technical support and Dr. Dong-xia Ye for administrative assistance.

Grant Support
This study was supported by research grant 2007BA118B03 from National Key Technology R&D Program of China (Z.Y. Zhang); research grants 3097344 and 81272979 from National Natural Science Foundation of China (L.P. Zhong); and research grant 10Da1951300 from Science and Technology Commission of Shanghai Municipality (C.P. Zhang).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked ‘advertisement’ in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 18, 2012; revised February 25, 2013; accepted February 26, 2013; published OnlineFirst March 20, 2013.

References
Cyclin D1 and TPF Induction Chemotherapy in OSCC


Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-12-1013

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2013/03/20/1535-7163.MCT-12-1013.DC1

Cited articles
This article cites 36 articles, 8 of which you can access for free at:
http://mct.aacrjournals.org/content/12/6/1112.full.html#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
/content/12/6/1112.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.